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Pemetrexed is a novel, multitargeted antifolate chemotherapeutic drug initially approved for the treatment of mesothelioma, but with 
well-documented activity in the treatment of non-
small cell lung cancer (NSCLC) and other malignan-
cies.1,2 Although its main mechanism of action is to 
inhibit thimidylate synthetase and thus interferes 
with pyrimidine synthesis, it also inhibits dihydrofo-
late reductase and glycanamide ribonucleotide formyl 
transferase, enzymes required for purine synthesis. Its 
therapeutic efficacy in NSCLC has been documented 
in large randomized studies where it has been proven 
equivalent to docetaxel as a second-line agent3 and at 
least equivalent to gemcitabine, and likely better for 
adenocarcinoma, when combined with platinum as 
first-line treatment.4 In the former study, the safety 
profile was better in pemetrexed-treated patients. 
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BACkgROunD AnD OBjECtIvEs: pemetrexed is a multitargeted folate pathway inhibitor with documented 
activity in non-small cell lung cancer (nsclc). the presumed maximum tolerated dose is 500 mg/m2 every 3 
weeks, but pemetrexed-related toxicity is ameliorated when folate and b12 supplementation is provided and 
therefore a higher dose intensity may be tolerated. the current exploratory study assessed the feasibility of 
administration of pemetrexed at a fixed dose of 1000 mg every 2 weeks in patients with relapsed or refractory 
nsclc. 
PAtIEnts AnD MEthODs: the first cohort of 12 patients received pemetrexed monotherapy. no dose-limiting 
grade 4 toxicity was noted after 4 cycles, so the subsequent cohort of 14 patients received additional anticancer 
agents (bevacizumab, erlotinib, carboplatin, docetaxel, vinorelbine) given along with dose-dense pemetrexed. 
REsuLts: toxicity overall was reversible and manageable. among 19 patients who received pemetrexed either 
alone or with non-myelosuppressive targeted agents, there were only 2 instances of grade 4 neutropenia after 
prolonged treatment. Grade 3-4 hematologic toxicity was eventually noted in 11 of the 26 patients (42%; 95% 
confidence interval, 23% to 61%) after a median of 4 cycles (range, 2-14 cycles). there was no significant ad-
ditional toxicity nor any treatment-related deaths. 
COnCLusIOn: our preliminary observations indicate that dose-dense pemetrexed every 2 weeks is feasible 
and this regimen can be used as monotherapy. these data may serve as a scaffold for combination studies. 
Specifically, pemetrexed at 500 mg/m2 every 3 weeks 
produced only a 5.3% rate of grade 3 and 4 neutro-
penia. This favorable profile results from vitamin 
B12 and folate supplementation, which is currently 
routinely coadministered. In fact, the mesothelioma 
phase 3 study had to be amended to mandate vitamin 
supplementation.5 
 Because of reduced hematologic toxicity, peme-
trexed should be safe to use in combination with 
other drugs, and combinations have been explored or 
are under investigation.6 A dose-intensified schedule 
of higher dose of pemetrexed given every 3 weeks has 
been shown to be well tolerated, albeit without obvi-
ous clinical benefit.7 Dose intensification by increas-
ing administration frequency (dose-dense adminis-
tration) is an effective approach in the treatment of 
lymphoma and breast cancer.8 The currently approved 
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dosage of pemetrexed at 500 mg/m2 every 3 weeks 
was established as the maximum tolerated dose prior 
to the awareness of the alleviation of the hematologic 
toxicity conferred by vitamin supplementation.9 In 
the current study we present the feasibity of a dose-
dense, every–2-week administration of pemetrexed 
in patients with relapsed and refractory NSCLC, as 
monotherapy. The data from this study should serve 
as a potentially useful base for combination studies. 
PAtIEnts AnD MEthODs 
Patients with a histologic or cytologic diagnosis of 
NSCLC with relapsed or refractory disease were 
considered for enrollment in the study. Eligible pa-
tients met the following criteria: at least one prior 
chemotherapy regimen for advanced disease, no prior 
pemetrexed exposure, Eastern Cooperative Oncology 
Group performance status of 0-3, granulocyte count 
>2500/mm3, platelet count >150000/mm3, serum 
creatinine level of <1.5 mg/dL, normal levels of trans-
aminases and bilirubin, life expectancy >3 months 
and at least a 3-week washout period from preced-
ing chemotherapy. All patients signed an Institutional 
Review Board-approved consent form and were treat-
ed at Interbalkan Medical Center in Thessaloniki, 
province of Macedonia, Greece. 
All patients underwent routine clinical and labo-
ratory investigation at baseline, including disease 
assessment by CT scans. Patients received a fixed 
pemetrexed dose of 1000 mg as a 15-minute intrave-
nous infusion. The administration was repeated ev-
ery 2 weeks, until disease progression or intolerance. 
Patients received vitamin supplementation with 1 mg 
of B12 every 8 weeks given intravenously and folic 
acid 700-1250 mcg, both beginning on day 1, prior 
to the administration of pemetrexed. A dose of 8 mg 
of dexamethasone was given as premedication along 
with antiemetics. Granulocyte-stimulating growth 
factors were allowed for secondary prophylaxis for 
grade 4 neutropenia, and following treatment delay, 
for neutropenia. Erythropoetin was administered for 
a hemoglobin level below 10 g/dL. Tumor measure-
ments were performed after the 4th cycle (8th week of 
treatment) and every 4 cycles thereafter or upon evi-
dence of progression. RECIST (Response Evaluation 
Criteria In Solid Tumors) criteria and National 
Cancer Institute Common Toxicity Criteria version 
3.0 were used for response and toxicity assessment. 
Chemotherapy administration was allowed if the ab-
solute neutrophil count was >1500/mm3, platelets 
>100 000/mm3 and all other toxicity had returned to 
grade 1 or less, except for anemia, or else treatment 
was postponed by a maximum of 1 week. If a delay 
was again required at subsequent cycles, a 25% dose 
reduction of pemetrexed (750 mg) was allowed once. 
No further dose attenuation or delay >week was  per-
mitted. 
The first cohort of 12 patients received pemetrexed 
monotherapy and were assessed for toxicity after all 
had completed 4 cycles (stage 1). If the safety criteria 
described below were met, subsequent patients were 
allowed to receive combinations with other agents, 
based on the pemetrexed 1000 mg every 2 weeks 
schedule (stage 2); the choice of the accompanying 
drugs was left to the judgement of the treating physi-
cian and was not controlled by the study design. The 
experimental part of the study remained the biweekly 
administration of pemetrexed. 
This was a preliminary study of a new treatment 
schedule for an established drug. At the first stage, 
12 patients were enrolled and analyzed for safety. If 
no toxicity or at maximum only one grade 4 toxic-
ity was noted after all 12 patients completed 4 cycles, 
the study was expanded to include additional patients 
who received the same dose of pemetrexed every 2 
weeks in combination with other agents. If more 
than one incident of grade 4 toxicity occurred, the 
study would have been terminated. The premise of 
this design is that if none of the 12 patients experi-
enced grade 4 toxicity during the observation period 
of 4 cycles, then the true incidence of grade 4 toxicity 
is below 25% (a<0.05) and for 1 occurrence <35% 
(a<0.05), respectively. 
REsuLts 
Between April 2006 and October 2008, 26 patients 
enrolled with a median age of 67 years (Table 1). The 
majority of patients had adenocarcinoma, although in 
the beginning of the study patients with squamous 
cell histology were included, as the impact of histol-
ogy on outcome was not known at that time. Median 
body surface (BS) was 1.86 m2 (range, 1.7-2.03 m2). 
Pemetrexed was a second-line regimen for the major-
ity of patients. Patients received a median of 4 cycles 
(range 1-14 cycles). 
Pemetrexed monotherapy (Stage 1) 
The first cohort of 12 patients (group A) that received 
pemetrexed monotherapy had the following charac-
teristics: male 10, female 2; performance status 0 in 
2 patients, performance status 1 in 3 patients, perfor-
mance status 2 in 5 patients and performance status 
3 in 2 patients. The patients had received a median 
of 1 prior chemotherapy courses (range, 1-4 courses). 
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The patients received a median of 4 pemetrexed cycles 
every 2 weeks (range of 2-12 cycles). Disease progres-
sion was the reason for treatment discontinuation for 
all patients. No grade 4 toxicity was observed in any 
of the patients while on pemetrexed treatment for the 
first 4 cycles, so that the premise of the study was ful-
filled, thus establishing safety of this approach (Table 
2). A treatment delay of 1 week was only required in 
the two instances of grade 3 neutropenia. Toxicity en-
Table 1. Patient characteristics.
  Group A Group B Total 
   n 12 14 26 
   male/female 10/2 10/4 20/6 
   Stage 3b/4 3/9 5/9 8/18 
   Prior courses 
     1 
     2 













   eCOg performance 
   status (0/1/2/3) 2/3/5/2 3/8/3/1 5/11/8/3 
   Histology 
   (adenocarcinoma
    large cell/
    squamous cell) 
4/1/7 11/3/0 15/4/7 
   median body 
   surface area (m2) 1.84 1.86 1.86 
Table 2. Stage 1 grade 3-4 toxicity.  
  Neutropenia Anemia Thrombocytopenia 
grade 3 2 /12 3/12 0 
grade 4 0 0 0 
Stage 1 involved 12 patients receiving pemetrexed 1000 mg every 2 weeks for an observation period of up to 4 cycles. 











   grade 3-4 neutropenia 3 (25%) 5 (26%) 7 (26%) 
   grade 3-4 anemia 3 (25%) 3 (16%) 7 (26%) 
   grade 3-4 
   thrombocytopenia 0 1 (6%) 3 (12%) 
   Other grade 3 toxicity 
   (no. patients) Fatigue (1) rash (1) 
Febrile 
neutropenia (1) 
 The table presents grade 3-4 toxicity at any cycle during each patient’s treatment. Patients received 2-14 cycles. 
The “pemetrexed +/- non myelosuppresive” regimen group combines the toxicity outcomes of patients who either 
received pemetrexed monotherapy or in combination with bevacizumab and/or erlotinib.  
countered after the 4th cycle is discussed below. 
Combinations with other agents (Stage 2) 
Subsequently enrolled patients (n=14) received peme-
trexed-based combinations (group B). Pemetrexed was 
combined with presumably non-myelotoxic, targeted 
agents in 7 patients (bevacizumab 10 mg/kg every 2 
weeks in 5 patients, erlotinib 150 mg daily in one pa-
tient, and both in 1 patient). In 7 patients, pemetrexed 
was coadministered with cytotoxic chemotherapy also 
given every 2 weeks (docetaxel 50 mg/m2 in 1 patient, 
carboplatin AUC 4 mg/hours×min (area under the 
concentration versus time curve in mg/mL×min) in 
4 patients, vinorelbine 25 mg/m2 in 1 patient, cispla-
tin 50 mg/m2, 1 patient). The most common toxicity 
encountered was hematologic, which was easily man-
aged and reversible. As expected, hematologic toxicity 
was more common in patients who received concur-
rent chemotherapy. Overall, grade 3 or 4 hematologic 
toxicity of one or more lineages was observed in 11 of 
the 26 patients (42%; 95% confidence interval, 23% 
to 61%); grade 3-4 neutropenia was observed in 7, 
grade 3 anemia in 7 and thrombocytopenia grade 3 in 
3 patients. Hematopoetic growth factor was at some 
point administered in 13 patients (including patients 
with grade 2 neutropenia). Dose reduction of peme-
trexed was required in 2 patients after the 6th and 9th 
cycle. There was no apparent association of toxicity 
with BSA. 
Biweekly pemetrexed with or without targeted 
agents 
Among patients who did not receive concurrent my-
elotoxic chemotherapy, i.e. monotherapy or combina-
tion with either bevacizumab or erlotinib, hemato-
logic toxicity grade 3 or 4 was observed at any time 
in 7 of the 19 patients (37%; 95% confidence interval, 
18% to 56%), after a median of 7 cycles. In particu-
lar, grade 3 anemia, grade 3-4 neutropenia or grade 3 
thrombocytopenia was observed in 3 (16%), 3 (16%) 
and 1 (5%) patient. Of interest, grade 4 neutropenia 
was only observed in long-term treated patients: one 
patient receiving pemetrexed monotherapy and one in 
combination with erlotinib, developed grade 4 neu-
tropenia after the 9th and 8th cycle, respectively. 
Non-hematologic toxicity 
Non hematologic toxicity was trivial and included a 
patient with grade 3 fatigue, a patient with superficial 
vein thrombosis of the arm and a patient who devel-
oped symptomatic eruption of both metatarsal areas 
(grade 2) prompting reverting to every 3 weeks peme-
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trexed after the 8th cycle. Brief febrile neutropenia 
occurred in one patient with PS 3. 
Tolerance of long-term pemetrexed 
Thirteen patients overall continued pemetrexed for over 
4 cycles. A trend for increased occurrence of neutrope-
nia or fatigue was observed after prolonged administra-
tion. One patient a receiving combination with bevaci-
zumab and one with erlotinib discontinued treatment 
after the 11th and 10th cycle because of fatigue grade 2 
persisting for over 3 weeks. Granulocyte colony stimu-
lating factor (GCSF) support was required for 5 of 7 
patients receiving dose-dense pemetrexed for over 8 cy-
cles, although these patients were not receiving a second 
myelotoxic chemotherapy agent. 
Disease assessment 
Although assessment of the efficacy of the regimen was 
not within the scope of this study, we observed the fol-
lowing outcomes: overall 4 patients achieved a partial 
response (PR), 9 patients had stable disease (SD) and 
13 patients had progressive disease (PD). The out-
comes for the group of pemetrexed monotherapy were 
as follows: 1 PR (8%), 4 SD (33.3%) and 7 PD (58%). 
The median time to progression (TTP) for the whole 
group was 8 weeks (range, 2-24 weeks). Six of the 7 
patients with squamous cell histology manifested pro-
gressive disease by the 4th cycle. The median TTP for 
patients with non-squamous histology was 14 weeks. 
After a median follow-up of 23 months, 4 patients 
remained alive 9-12 months after initiation of peme-
trexed treatment. 
DIsCussIOn 
Administration of second-line chemotherapy for 
NSCLC has been asscociated with a small survival ben-
efit.10-13 When selecting treatment for such patients, it is 
very important to provide palliation with minimal tox-
icity, and in that regard pemetrexed is a clinically useful 
choice. Our exploratory study was based on the fact that 
pemetrexed, when given with vitamin supplementation, 
is particularly safe with favorable toxicity profile com-
pared to other chemotherapeutic agents. The currently 
established dose approved by the regulatory authorities 
of 500 mg/m2 every 3 weeks was based on early phase 
1/2 studies where higher dosages caused deaths due to 
neutropenia, mucositis or other toxicity, and before the 
favorable impact of vitamin supplementation was fully 
understood.14 This became particularly apparent in the 
phase 3 study involving patients with mesothelioma 
which was amended in order to be safely concluded.15 
As the currently established standard pemetrexed 
administration resulted from dose-limiting toxicities 
observed in early studies without vitamin supplemen-
tation, it is expected that further dose escalation is 
possible, since vitamin B12 and folate are routinely 
administered in clinical practice. In fact, a regimen 
employing dose escalation to 1000 mg/m2 given every 
three weeks has been tested and has been compared 
to standard pemetrexed.16 Dose escalation was in-
deed feasible, with only slight exacerbation of toxic-
ity. Unfortunately, no dose response correlation could 
be shown. Another trial employing intensified peme-
trexed dosage tested the combination of gemcitabine 
with standard-dose pemetrexed given every 2 weeks in 
previously untreated patients;17 a response of 20.8% 
with clinical benefit in two-thirds of the patients was 
noted. Toxicity was manageable in this group of che-
motherapy-naïve patients. 
Our study addresses the question of feasibility of 
increasing dose intensity by increasing the dose density 
of pemetrexed in relapsed NSCLC patients, includ-
ing those with relatively reduced performance status. 
Dose dense administration of chemotherapy offers 
theoretical advantages arising from the Gompertzian 
or sigmoidal kinetics of tumor growth, which is in-
versely proportional to total tumor mass, thus enabling 
in theory a more steep overall tumor reduction.18 This 
approach has resulted in the increased efficacy of stan-
dard-dose chemotherapy in aggressive lymphoma and 
there is also evidence of an advantage in breast cancer 
and perhaps other tumor types.19,20 Our study docu-
mented the feasibility of administering pemetrexed at 
a fixed dose of 1000 mg every 2 weeks in relapsed or 
refractory patients, with vitamin supplementation. The 
observed toxicity was within an acceptable range and 
not dissimilar from what is expected in such a cohort. 
Furthermore, after having shown the safety of dose-
dense pemetrexed, our limited study provides some 
evidence that combinations, especially with targeted 
non-myelosuppressive agents or with classical che-
motherapy, may be possible in patients with relapsed 
NSCLC. The clinical benefit of such combinations is 
implied by early preclinical and clinical studies.21,22 In 
addition, on the assumption that the maximum toler-
ated dose of pemetrexed is not the one approved by the 
regulatory agencies and because even higher doses of 
600 mg/m2 every 3 weeks were sufficiently tolerable 
in early phase 2 studies, our patients received a fixed 
dose of 1000 mg.23 A typical patient, assuming a 1.8 m2 
body surface, receives 900 mg, whereas our smaller pa-
tient received the equivalent of 588 mg/m2 deemed to 
be safe. Thus the variability of the actual dosage per m2 
delivered to our patients, combined with the feasibility 
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of essentially doubling each dose as mentioned above, 
renders the design of our study reasonably safe. The po-
tential merit of our findings should perhaps be tested in 
larger studies and weighed against the use of growth fac-
tors often required after prolonged administration. 
In conclusion, our study indicates that pemetrexed 
can safely be given at the fixed dose of 1000 mg every 
two weeks in patients with relapsed non small cell lung 
cancer, when folate and vitamin B12 is provided. This 
dose-dense regimen may be a useful scaffold for devel-
oping combination regimens of potential usefulness in 
the treatment of patients with lung cancer. Clearly, larg-
er studies are required to assess the potential benefit of 
such an approach. 
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